跳至主要内容
临床试验/NCT02428010
NCT02428010终止不适用

Evaluation of Safety and Performance of the Twelve Transcatheter Mitral Valve Replacement System in Patients With Severe, Symptomatic Mitral Regurgitation

Medtronic Cardiovascular1 个研究点 分布在 1 个国家目标入组 3 人开始时间: 2014年9月1日最近更新:
适应症

试验速览

阶段
不适用
状态
终止
发起方
入组人数
3
试验地点
1
主要终点
Adverse Events

研究概览

简要总结

Study to evaluate the safety and performance of the Twelve TMVR System

详细描述

The study is a prospective, multi-center, non-randomized trial to evaluate the safety and performance of the Twelve TMVR System in very high risk patients with severe, symptomatic mitral regurgitation.

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Single Group
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Severe mitral regurgitation (MR Grade 3-4+)
  • Symptomatic mitral regurgitation (NYHA Class II-IV)
  • Trans-apical access deemed feasible by the treating physician
  • Native mitral valve geometry and size compatible with the Twelve TMVR

排除标准

  • Left ventricular ejection fraction (LVEF) < 20
  • Evidence of intracardiac mass, thrombus, or vegetation
  • Prior valve surgery or need for other valve surgery
  • Prior stroke within 4 weeks
  • Need for coronary revascularization
  • History of, or active, endocarditis
  • Renal insufficiency (Creatinine > 2.5 mg/dL)

结局指标

主要结局

Adverse Events

时间窗: 30 days

Number of patients with adverse events associated with the delivery and/or implantation of the device

次要结局

  • Reduction of MR(Through 5 years)
  • Procedural Success(Through 5 years)

研究者

发起方
Medtronic Cardiovascular
申办方类型
Industry
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验